Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.
暂无分享,去创建一个
D. Collins | M. Orton | N. Tunariu | M. Leach | N. deSouza | S. Kaye | V. Morgan | C. Messiou | H. Young | I. Castellano | H. Mann | J. Ang | D. Papadatos-Pastos | A. Brunetto | D. Mears | J. Tessier | D. Ghiorghiu | S. Marley | J. Debono
[1] Wei Wei,et al. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. , 2011, AJR. American journal of roentgenology.
[2] G J M Parker,et al. Comparison of dynamic contrast‐enhanced MRI and dynamic contrast‐enhanced CT biomarkers in bladder cancer , 2011, Magnetic resonance in medicine.
[3] S. Sourbron. Technical aspects of MR perfusion. , 2010, European journal of radiology.
[4] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Piotr Kozlowski,et al. Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. , 2010, Academic radiology.
[6] C. Ng,et al. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. , 2010, AJR. American journal of roentgenology.
[7] D L Buckley,et al. Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix , 2009, British Journal of Cancer.
[8] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[9] David Atkinson,et al. Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours , 2009, Physics in medicine and biology.
[10] Rajesh Odedra,et al. Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. , 2009, Magnetic resonance imaging.
[11] T. Vogl,et al. Functional CT of squamous cell carcinoma in the head and neck: repeatability of tumor and muscle quantitative measurements, inter- and intra-observer agreement , 2008, European Radiology.
[12] J. Waterton,et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast‐enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol) , 2008, NMR in biomedicine.
[13] Angela Caunce,et al. Tracer kinetic model–driven registration for dynamic contrast‐enhanced MRI time‐series data , 2007, Magnetic resonance in medicine.
[14] J. Drevs,et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Geoff J M Parker,et al. Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.
[16] H. Cheng. Dynamic contrast-enhanced MRI in oncology drug development. , 2007, Current clinical pharmacology.
[17] David Atkinson,et al. Using Registration to Quantify the Consistency of Whole Liver Position during Patient Breath-hold in Dynamic Contrast-Enhanced MRI , 2007 .
[18] Wolfhard Semmler,et al. Dual‐bolus approach to quantitative measurement of pulmonary perfusion by contrast‐enhanced MRI , 2006, Journal of magnetic resonance imaging : JMRI.
[19] A. Jackson,et al. Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI , 2006, Magnetic resonance in medicine.
[20] Geoff J M Parker,et al. Comparison of errors associated with single‐ and multi‐bolus injection protocols in low‐temporal‐resolution dynamic contrast‐enhanced tracer kinetic analysis , 2006, Magnetic resonance in medicine.
[21] E. Eisenhauer,et al. RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.
[22] Ernst Klotz,et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. , 2006, Radiology.
[23] John Suckling,et al. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.
[24] S. Barry,et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.
[25] M. Knopp,et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations , 2005, British Journal of Cancer.
[26] M. Beer,et al. Prebolus quantitative MR heart perfusion imaging , 2004, Magnetic resonance in medicine.
[27] J. Heiserman,et al. Assessment of the reproducibility of postprocessing dynamic CT perfusion data. , 2004, AJNR. American journal of neuroradiology.
[28] K. Miles,et al. Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.
[29] A. Padhani,et al. Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.
[30] A. Padhani,et al. Reproducibility of quantitative dynamic MRI of normal human tissues , 2002, NMR in biomedicine.
[31] S. O. Oyadiji,et al. Application of coefficient of variation in reliability-based mechanical design and manufacture , 2001 .
[32] Daniel Rueckert,et al. Nonrigid registration using free-form deformations: application to breast MR images , 1999, IEEE Transactions on Medical Imaging.
[33] D. Altman,et al. Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.
[34] Ting-Yim Lee,et al. An Adiabatic Approximation to the Tissue Homogeneity Model for Water Exchange in the Brain: I. Theoretical Derivation , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] B K Rutt,et al. Temporal sampling requirements for the tracer kinetics modeling of breast disease. , 1998, Magnetic resonance imaging.
[36] P. Burton,et al. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. , 1998, Statistics in medicine.
[37] N J Pelc,et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. , 1987, Magnetic resonance imaging.
[38] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.